Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
10 Juin 2022 - 2:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY
TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-39425
Checkmate Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
245 Main Street, 2nd Floor
Cambridge, MA 02142
(617) 682-3625
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Common Stock, par value
$0.0001 per share
(Title of each class of securities
covered by this Form)
N/A
(Titles of all other classes of securities for
which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate
the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) |
x |
Rule 12g-4(a)(2) |
¨ |
Rule 12h-3(b)(1)(i) |
x |
Rule 12h-3(b)(1)(ii) |
¨ |
Rule 15d-6 |
¨ |
Rule 15d-22(b) |
¨ |
Approximate number of holders of record as of
the certification or notice date: one (1).
Pursuant to the requirements of the Securities
Exchange Act of 1934, Checkmate Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned
duly authorized person.
Date: June 10, 2022 |
Checkmate Pharmaceuticals, Inc. |
|
|
|
|
By: |
/s/ Nouhad Husseini |
|
Name: |
Nouhad Husseini |
|
Title: |
Managing Director |
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Checkmate Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Checkmate Pharmaceuticals, Inc.